CURIS, INC. Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value
CURIS, INC. (CRIS) reported Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value of $2.08 per share for the 12-month period ending 2025-12-31, per its 10-K filed 2026-03-24.
Financial Statements › Notes › Compensation Related Costs › Share-Based Payment Arrangement, Disclosure
us-gaap:ShareBasedCompensationArrangementByShareBasedPaymentAwardOptionsGrantsInPeriodWeightedAverageGrantDateFairValue · last filed 2026-08-14
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2025-03-31 was $2.67, a 73.33% decline year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2024-03-31 was $10.01, a 15.17% decline year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2023-03-31 was $11.80, a 350.38% increase year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for the quarter ending 2022-03-31 was $2.62, a 71.30% decline year-over-year.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2025 was $2.08, a 78.11% decline from fiscal 2024.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2024 was $9.50, a 18.80% decline from fiscal 2023.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2023 was $11.70, a 72.66% decline from fiscal 2022.
- CURIS, INC. share-based compensation arrangement by share-based payment award, options, grants in period, weighted average grant date fair value for fiscal 2022 was $42.80, a 490.34% increase from fiscal 2021.
| Period end | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 3 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 6 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 9 month as first filed | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month | Share-based Compensation Arrangement by Share-based Payment Award, Options, Grants in Period, Weighted Average Grant Date Fair Value 12 month as first filed |
|---|---|---|---|---|---|---|---|---|---|
| 2025-12-31 | $2.08 10-K · filed 2026-03-24 | ||||||||
| 2025-09-30 | $2.13 10-Q · filed 2025-11-06 | ||||||||
| 2025-06-30 | $42.60 10-Q · filed 2026-08-14 | $2.13 10-Q · filed 2025-08-05 | |||||||
| 2025-03-31 | $2.67 10-Q · filed 2026-05-13 | ||||||||
| 2024-12-31 | $9.50 10-K · filed 2026-03-24 | ||||||||
| 2024-09-30 | $9.50 10-Q · filed 2025-11-06 | ||||||||
| 2024-06-30 | $9.71 10-Q · filed 2025-08-05 | ||||||||
| 2024-03-31 | $10.01 10-Q · filed 2025-05-06 | ||||||||
| 2023-12-31 | $11.70 10-K · filed 2025-03-31 | ||||||||
| 2023-09-30 | $12.00 10-Q · filed 2024-11-14 | ||||||||
| 2023-06-30 | $12.01 10-Q · filed 2024-08-01 | $0.60 10-Q · filed 2023-08-03 | |||||||
| 2023-03-31 | $11.80 10-Q · filed 2024-05-07 | $0.59 10-Q · filed 2023-05-04 | |||||||
| 2022-12-31 | $42.80 10-K · filed 2024-02-08 | $2.14 10-K · filed 2023-03-13 | |||||||
| 2022-09-30 | $43.60 10-Q · filed 2023-11-02 | $2.18 10-Q · filed 2022-11-09 | |||||||
| 2022-06-30 | $2.57 10-Q · filed 2023-08-03 | ||||||||
| 2022-03-31 | $2.62 10-Q · filed 2023-05-04 | ||||||||
| 2021-12-31 | $7.25 10-K · filed 2023-03-13 | ||||||||
| 2021-09-30 | $9.21 10-Q · filed 2022-11-09 | ||||||||
| 2021-06-30 | $9.42 10-Q · filed 2022-08-04 | ||||||||
| 2021-03-31 | $9.13 10-Q · filed 2022-05-05 | ||||||||
| 2020-12-31 | $0.84 10-K · filed 2022-02-24 | ||||||||
| 2020-09-30 | $0.75 10-Q · filed 2021-11-09 | ||||||||
| 2020-06-30 | $0.75 10-Q · filed 2021-08-03 | ||||||||
| 2020-03-31 | $0.76 10-Q · filed 2021-05-12 | ||||||||
| 2019-12-31 | $0.85 10-K · filed 2022-02-24 | ||||||||
| 2019-09-30 | $0.83 10-Q · filed 2020-11-10 | ||||||||
| 2019-06-30 | $0.79 10-Q · filed 2020-08-04 | ||||||||
| 2019-03-31 | $0.76 10-Q · filed 2020-05-12 | ||||||||
| 2018-12-31 | $1.46 10-K · filed 2020-03-19 | ||||||||
| 2018-09-30 | $1.46 10-Q · filed 2019-11-05 | ||||||||
| 2018-06-30 | $1.73 10-Q · filed 2019-08-09 | ||||||||
| 2018-03-31 | $2.04 10-Q · filed 2019-05-14 | $0.41 10-Q · filed 2018-05-03 | |||||||
| 2017-12-31 | $1.43 10-K · filed 2019-03-26 | ||||||||
| 2017-09-30 | $7.15 10-Q · filed 2018-11-01 | $2.51 10-Q · filed 2017-11-07 | |||||||
| 2017-06-30 | $7.25 10-Q · filed 2018-08-02 | $2.53 10-Q · filed 2017-08-03 | |||||||
| 2017-03-31 | $1.44 10-Q · filed 2018-05-03 | $2.52 10-Q · filed 2017-05-04 | |||||||
| 2016-12-31 | $1.11 10-K · filed 2018-03-08 | $1.73 10-K · filed 2017-03-09 | |||||||
| 2016-09-30 | $1.08 10-Q · filed 2017-11-07 | ||||||||
| 2016-06-30 | $1.07 10-Q · filed 2017-08-03 | ||||||||
| 2016-03-31 | $1.07 10-Q · filed 2017-05-04 | ||||||||
| 2015-12-31 | $1.71 10-K · filed 2018-03-08 | ||||||||
| 2015-09-30 | $1.71 10-Q · filed 2016-11-03 | ||||||||
| 2015-06-30 | $1.71 10-Q · filed 2016-08-04 | ||||||||
| 2015-03-31 | $1.25 10-Q · filed 2016-05-09 | ||||||||
| 2014-12-31 | $1.79 10-K · filed 2017-03-09 | ||||||||
| 2014-09-30 | $1.79 10-Q · filed 2015-11-09 | ||||||||
| 2014-06-30 | $1.82 10-Q · filed 2015-08-06 | ||||||||
| 2014-06-02 | $0.34 10-K · filed 2018-03-08 | ||||||||
| 2014-03-31 | $1.97 10-Q · filed 2015-05-07 | ||||||||
| 2014-02-18 | $1.20 10-K · filed 2018-03-08 | ||||||||
| 2013-12-31 | $2.27 10-K · filed 2016-02-29 | ||||||||
| 2013-09-30 | $2.29 10-Q · filed 2014-11-10 | ||||||||
| 2013-06-30 | $2.14 10-Q · filed 2014-08-07 | ||||||||
| 2013-03-31 | $2.14 10-Q · filed 2014-05-09 | ||||||||
| 2012-12-31 | $2.99 10-K · filed 2015-02-24 | ||||||||
| 2012-09-30 | $2.99 10-Q · filed 2013-11-12 | ||||||||
| 2012-06-30 | $2.99 10-Q · filed 2013-08-08 | ||||||||
| 2012-03-31 | $2.99 10-Q · filed 2013-05-09 | ||||||||
| 2011-12-31 | $1.72 10-K · filed 2014-03-13 | ||||||||
| 2011-09-30 | $1.45 10-Q · filed 2012-11-06 | ||||||||
| 2011-06-30 | $1.43 10-Q · filed 2012-08-09 | ||||||||
| 2010-12-31 | $1.46 10-K · filed 2013-03-13 |
Similar stocks
| Stock Name | Country | Market Cap | PE Ratio |
|---|---|---|---|
| Silexion Therapeutics Corp (SLXN) | $0.001B | ||
| Calidi Biotherapeutics, Inc. (CLDI) | United States | $0.003B | |
| VivoSim Labs, INC. (VIVS) | United States | $0.003B | |
| WINDTREE THERAPEUTICS INC /DE/ (WINT) | United States | $0.003B | -0.32 |
| PharmaCyte Biotech, Inc. (PMCB) | United States | $0.005B | |
| AIM ImmunoTech Inc. (AIM) | United States | $0.006B | |
| CREATIVE MEDICAL TECHNOLOGY HOLDINGS, INC. (CELZ) | United States | $0.006B | |
| CERO THERAPEUTICS HOLDINGS, INC. (CERO) | United States | $0.007B | |
| TScan Therapeutics, Inc. (TCRX) | United States | $0.008B | -1.23 |
| Senti Biosciences Holdings, Inc. (SNTI) | United States | $0.011B | -0.70 |